{"id":1769,"date":"2026-08-28T03:43:55","date_gmt":"2026-08-28T03:43:55","guid":{"rendered":"https:\/\/isbm-blow-molding.com\/?p=1769"},"modified":"2026-08-28T03:43:55","modified_gmt":"2026-08-28T03:43:55","slug":"10-year-total-cost-of-ownership-for-an-injection-blow-molding-machine","status":"publish","type":"post","link":"https:\/\/isbm-blow-molding.com\/ru\/10-year-total-cost-of-ownership-for-an-injection-blow-molding-machine\/","title":{"rendered":"\u041e\u0431\u0449\u0430\u044f \u0441\u0442\u043e\u0438\u043c\u043e\u0441\u0442\u044c \u0432\u043b\u0430\u0434\u0435\u043d\u0438\u044f \u043c\u0430\u0448\u0438\u043d\u043e\u0439 \u0434\u043b\u044f \u043b\u0438\u0442\u044c\u044f \u043f\u043e\u0434 \u0434\u0430\u0432\u043b\u0435\u043d\u0438\u0435\u043c \u0441 \u0432\u044b\u0434\u0443\u0432\u043d\u044b\u043c \u0444\u043e\u0440\u043c\u043e\u0432\u0430\u043d\u0438\u0435\u043c \u0437\u0430 10 \u043b\u0435\u0442."},"content":{"rendered":"
\n

<\/p>\n

\n
<\/div>\n
<\/div>\n
\n
\n
<\/div>\n

10-YEAR TCO \u00b7 IBM MACHINE \u00b7 CAPEX ENERGY MAINTENANCE TOOLING \u00b7 EP-ZQ KOREA EVER-POWER<\/span><\/p>\n

<\/div>\n<\/div>\n

10-Year Total Cost of Ownership
\nfor an Injection<\/span>
\n\u041c\u0430\u0448\u0438\u043d\u0430 \u0434\u043b\u044f \u0432\u044b\u0434\u0443\u0432\u043d\u043e\u0433\u043e \u0444\u043e\u0440\u043c\u043e\u0432\u0430\u043d\u0438\u044f<\/span>:
\nEP-ZQ TCO Analysis<\/h1>\n

The IBM machine purchase price is 18\u201332% of the true 10-year total cost of ownership at Korean pharmaceutical and cosmetic production scale. Energy, maintenance, tooling amortisation, downtime opportunity cost and resin waste each contribute meaningfully to the per-bottle cost that determines whether a ZQ135 at 18 cavities or a ZQ110 at 14 cavities delivers better unit economics for your annual volume. This guide provides the complete 10-year TCO model for EP-ZQ80, ZQ110 and ZQ135, with cost-per-bottle output and breakeven analysis across three production scenarios.<\/p>\n

CAPEX \u00b7 Energy \u00b7 Maintenance \u00b7 Tooling \u00b7 Downtime \u00b7 10-Year Model<\/span>
\nZQ80 vs ZQ110 vs ZQ135 \u00b7 Cost-per-Bottle \u00b7 Breakeven Analysis<\/span><\/div>\n

KOREA EVER-POWER \u00b7 \u0410\u041d\u0421\u0410\u041d-\u0421\u0418, \u0413\u0401\u041d\u0413\u0418-\u0414\u041e \u00b7 \u0410\u0412\u0413\u0423\u0421\u0422 2026 \u00b7 \u041f\u041e\u0421\u041b\u0415\u0414\u041d\u0415\u0415 \u041e\u0411\u041d\u041e\u0412\u041b\u0415\u041d\u0418\u0415: \u0410\u0412\u0413\u0423\u0421\u0422 2026<\/p>\n<\/div>\n<\/header>\n

<\/p>\n

\n
\n
<\/div>\n

10-YEAR IBM TCO \u00b7 KEY FINDINGS \u00b7 AUGUST 2026<\/p>\n<\/div>\n

\n
\n

CAPEX AS % OF TCO<\/p>\n

18\u201332%<\/p>\n

Machine purchase price is 18\u201332% of true 10-year TCO. At ZQ135 running 18-cavity 100ml PP pharmaceutical at 3-shift Korean production: 10-year TCO \u2248 KRW 3.85B. Machine CAPEX \u2248 KRW 750M\u20131.1B (19\u201329%). Energy is 22\u201328%; maintenance 9\u201312%; tooling 14\u201318%; downtime opportunity 8\u201315% of 10-year TCO.<\/p>\n<\/div>\n

\n

COST PER BOTTLE (ZQ135)<\/p>\n

KRW 2.1\u20133.8<\/p>\n

10-year fully-loaded IBM machine cost per bottle at ZQ135 \/ 18-cavity \/ 100ml PP \/ 3-shift \/ 330 days: KRW 2.1\u20133.8 per bottle (range reflects variable downtime and energy tariff scenarios). Excludes resin cost (KRW 45\u201385\/bottle for PP HPP at 33g preform) and filling\/packaging downstream costs. IBM machine cost is typically 3\u20138% of finished pharmaceutical product CMO cost.<\/p>\n<\/div>\n

\n

ZQ135 vs ZQ110 TCO CROSSOVER<\/p>\n

120M\/year<\/p>\n

Below 120M bottles\/year at 100ml: ZQ110 (14 cavities) has lower 10-year TCO than ZQ135 (18 cavities) \u2014 ZQ135 CAPEX premium not recovered at lower utilisation. Above 120M\/year: ZQ135 per-bottle cost falls below ZQ110 and continues improving with volume. At 193M\/year (full ZQ135 capacity at 100ml): ZQ135 per-bottle cost is 31\u201338% lower than equivalent ZQ110 pairs.<\/p>\n<\/div>\n

\n

DOWNTIME LEVERAGE<\/p>\n

KRW 420M<\/p>\n

Difference in 10-year downtime opportunity cost between best-practice preventive maintenance (4.2 hr\/month unplanned) and reactive-only maintenance (16.8 hr\/month) at ZQ135 100ml pharmaceutical: KRW 420\u2013504M over 10 years. Downtime cost is the single largest TCO variable \u2014 more sensitive than energy tariff or tooling amortisation schedule.<\/p>\n<\/div>\n<\/div>\n<\/div>\n

<\/p>\n